Literature DB >> 308151

Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion.

Y M Wang, P Y Kim, E Lantin, D C van Eys, M M Romsdahl, W W Sutow.   

Abstract

Plasma methotrexate (MTX) concentrations were quantitated in 34 patients after 127 high-dose (35--350 mg/kg) infusions with citrovorum factor rescue. Significant linear correlations have been obtained between methotrexate dosage and concentrations in plasma at 6 and 24 hours after the initiation of the therapy. However, similar trends have not been observed when 48- and 72-hour samples were analyzed. Clinical toxicity was not serious when the methotrexate level in plasma was less than 4.5 X 10(-6) M at 48 hours after the start of a six-hour infusion in children. A minimal four-hour steady-state methotrexate plasma level can be maintained during a six-hour infusion. Children excrete methotrexate at a faster rate than adults; the half-life of MTX during the first phase of plasma clearance curve is one hour shorter in children. Urinary analyses have indicated that substantial methotrexate is metabolized. The chemical nature of these components has not been identified. Further, the urinary metabolic profiles varied among patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308151     DOI: 10.1002/mpo.2950040305

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  5 in total

Review 1.  Clinical pharmacokinetics of methotrexate in children.

Authors:  Y M Wang; T Fujimoto
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

2.  [Multidrug chemotherapy of osteogenic sarcoma (author's transl)].

Authors:  G Prindull
Journal:  Blut       Date:  1979-10

3.  Pharmacokinetic study of indicine N-oxide in pediatric cancer patients.

Authors:  M M Ames; J S Miser; W A Smithson; P F Coccia; C S Hughes; D M Davis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

4.  Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.

Authors:  C R Pinkerton; S G Welshman; J G Kelly; R G Shanks; J M Bridges
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

5.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.